MedTrace Logo

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

NCT00183261 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-11-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether the HIV vaccine MRKAd5 HIV-1 gag/pol/nef followed by treatment interruption can increase immune system function in adults with acute or recent HIV infection who have started taking anti-HIV drugs.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

MRKAd5 HIV-1 gag/pol/nef

1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly

BIOLOGICAL

MRKAd5 HIV-1 gag/pol/nef placebo

1.0 mL administered intramuscularly

Sponsors & Collaborators

  • Acute Infection and Early Disease Research Program

    collaborator NETWORK

  • Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

    collaborator NETWORK

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Susan Little, MD · University of California, San Diego AIDS Vaccine Research Center

  • Douglas D. Richman, MD · Departments of Pathology and Medicine, University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2007-08-31
Completion
2010-10-31

Countries

  • United States
  • American Samoa
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00183261 on ClinicalTrials.gov